BridgeBio Pharma Grants Equity to 36 New Employees
News related to:BridgeBio Pharma · 2 min read
PALO ALTO, Calif., Sept. 18, 2026 /CourierPR/ -- BridgeBio Pharma, a biopharmaceutical company focused on developing medicines for genetic conditions, has announced the approval of equity grants to 36 new employees on September 18, 2026. The grants, totaling 63,009 shares of the company’s common stock, are in the form of restricted stock units (RSUs).
According to the terms of the grants, one-fourth of the shares underlying each RSU will vest on November 16, 2027. The remaining shares will vest in one-twelfth increments on a quarterly basis thereafter, contingent upon the employees’ continued employment with the company. These inducement grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the company’s Equity Incentive Plan, which was adopted by the board of directors in November 2019 and subsequently amended and restated on February 10, 2023, and December 13, 2023.
The Equity Incentive Plan, which forms the basis for these grants, was designed to attract and retain key talent by providing a mix of equity and cash compensation. The terms of the plan reflect BridgeBio’s commitment to fostering a strong and dedicated workforce capable of driving innovation in the field of genetic medicine.
BridgeBio Pharma’s focus on genetic conditions and its mission to develop transformative medicines for underserved patient populations remain central to its strategic objectives. The company’s decentralized, hub-and-spoke model is designed to accelerate the development and delivery of innovative treatments, ensuring that patients have access to the latest advancements in genetic science.
The approval of these inducement grants underscores BridgeBio’s ongoing commitment to its employees and the advancement of genetic medicine. By aligning the interests of its employees with the company’s goals, BridgeBio aims to foster a culture of innovation and excellence.
In summary, the approval of these equity grants on September 18, 2026, is a significant step in BridgeBio’s ongoing efforts to build a strong and dedicated team. The terms of the grants, including the vesting schedule and the alignment with Nasdaq Listing Rule 5635(c)(4), reflect the company’s commitment to best practices in corporate governance and talent management.